Clinical Trial Search

Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9

Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04

Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002

Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline

Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit

Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214

Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001

Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008

Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core — 27; 29; 3; 3 participants

Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2

Primary: Peak 6-minute Walk Distance — 366.0; 360.0; 21.6; 3.0 meters — p=0.00044

Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg

Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg

Primary: Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks — 382.94; 351.18 meters

Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes

Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm

Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) — 33.3; 33.3; 33.3; 80.0 Percentage of Participants

Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume

Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg

Primary: Change in Pulmonary Vascular Resistance (PVR) at Three Months — -0.49 Wood units — p=0.09

Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…

Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68

Primary: Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD) — 20.5 meters — p=<0.001

Primary: Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to Ambrisentan — 90.7 percentage of participants

Primary: Pulmonary Vascular Resistance (PVR) — 64; 119; 67; 46 dyn*sec/cm^5

Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39

Primary: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population — 6.44; 13.40; 10.58; 10.24 percent change — p=0.056

Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05